[{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Intech Biopharm Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Intech Biopharm Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Intech Biopharm Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Synmosa","sponsor":"Synmosa","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Oxybutynin Hydrochloride","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Synmosa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Synmosa \/ Synmosa","highestDevelopmentStatusID":"1","companyTruncated":"Synmosa \/ Synmosa"},{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"GCP ClinPlus | Beijing Aicomer Pharmaceutical Technology | Key Tech | Healthcare Inc | Peking University People's Hospital | Beijing Friendship Hospital | Tianjin First Central Hospital | Bao Gang Hospital | The Affiliated Hospital of Inner Mongolia Medic","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"TAIWAN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Intech Biopharm Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intech Biopharm Ltd \/ GCP ClinPlus | Beijing Aicomer Pharmaceutical Technology | Key Tech | Healthcare Inc | Peking University People's Hospital | Beijing Friendship Hospital | Tianjin First Central Hospital | Bao Gang Hospital | The Affiliated Hospital of Inner Mongolia Medic","highestDevelopmentStatusID":"11","companyTruncated":"Intech Biopharm Ltd \/ GCP ClinPlus | Beijing Aicomer Pharmaceutical Technology | Key Tech | Healthcare Inc | Peking University People's Hospital | Beijing Friendship Hospital | Tianjin First Central Hospital | Bao Gang Hospital | The Affiliated Hospital of Inner Mongolia Medic"},{"orgOrder":0,"company":"Synmosa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elobixibat","moa":"||Ileal bile acid transporter","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Synmosa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Synmosa \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synmosa \/ Inapplicable"},{"orgOrder":0,"company":"Synmosa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Synmosa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Synmosa \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synmosa \/ Inapplicable"},{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"TAIWAN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Intech Biopharm Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intech Biopharm Ltd \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Intech Biopharm Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Microorganism","year":"2021","type":"Private Placement","leadProduct":"Decoy20","moa":"||Toll-like-4 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Intech Biopharm Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intech Biopharm Ltd \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Intech Biopharm Ltd \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||Beta-2 adrenergic receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Intech Biopharm Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Intech Biopharm Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Intech Biopharm Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||Beta-2 adrenergic receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Intech Biopharm Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Intech Biopharm Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Intech Biopharm Ltd \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Synmosa

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 13, 2025

                          Lead Product(s) : Oxybutynin Hydrochloride,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Recipient : National Taiwan University Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 25, 2023

                          Lead Product(s) : Azelastine Hydrochloride,Fluticasone Propionate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 09, 2023

                          Lead Product(s) : Elobixibat,Inapplicable

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 29, 2022

                          Lead Product(s) : Salbutamol Sulphate,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Budesonide,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Study Phase : Phase IV

                          Sponsor : GCP ClinPlus | Beijing Aicomer Pharmaceutical Technology | Key Tech | Healthcare Inc | Peking University People's Hospital | Beijing Friendship Hospital | Tianjin First Central Hospital | Bao Gang Hospital | The Affiliated Hospital of Inner Mongolia Medic

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          December 09, 2021

                          Lead Product(s) : Budesonide,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase IV

                          Sponsor : GCP ClinPlus | Beijing Aicomer Pharmaceutical Technology | Key Tech | Healthcare Inc | Peking University People's Hospital | Beijing Friendship Hospital | Tianjin First Central Hospital | Bao Gang Hospital | The Affiliated Hospital of Inner Mongolia Medic

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Decoy20 is single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          July 26, 2021

                          Lead Product(s) : Decoy20,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $30.0 million

                          Deal Type : Private Placement

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 03, 2021

                          Lead Product(s) : Salbutamol Sulphate,Inapplicable

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 18, 2021

                          Lead Product(s) : Salbutamol Sulphate,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          July 31, 2020

                          Lead Product(s) : Budesonide,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          August 01, 2016

                          Lead Product(s) : Budesonide,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank